Item 1.01. Entry Into a Material Definitive Agreement. OnOctober 25, 2021 ,AnaptysBio, Inc. ("AnaptysBio") entered into a Royalty Purchase Agreement (the "Royalty Purchase Agreement") withSagard Healthcare Royalty Partners, LP ("Sagard") to monetize a portion ofAnaptysBio's future JEMPERLI royalties and milestones underAnaptysBio's Collaboration and Exclusive License Agreement, as amended (the "Collaboration Agreement"), with Tesaro, Inc. andTesaro Development, Ltd. , each a wholly-owned subsidiary of GlaxoSmithKline ("GSK"). Upon closing of the transaction with Sagard, which is anticipated by the end of 2021, Sagard will payAnaptysBio $250 million upfront in exchange for royalties payable toAnaptysBio under the Collaboration Agreement on annual global net sales of JEMPERLI below$1 billion startingOctober 2021 . The royalty rate applicable below the$1 billion annual net sales threshold is 8%. Sagard may also receive up to a total of$105 million in potential cash milestones, of which$15 million are subject to certain future JEMPERLI regulatory filing and approval milestones and up to$90 million are subject to certain commercial sales milestones due prior to JEMPERLI achieving the$1 billion in annual global net sales threshold. Royalties payable above$1 billion JEMPERLI annual global net sales, which are paid by GSK at 12% to 25%, and certain milestones payable on annual sales at or above$1 billion are retained byAnaptysBio and are not subject to the Royalty Purchase Agreement. Royalties and milestones due upon development and commercialization of theAnaptysBio -generated anti-TIM-3 antagonist (cobolimab) or anti-LAG-3 antagonist (GSK4074386) antibodies under the Collaboration Agreement, including in combination with JEMPERLI, are also not subject to the Royalty Purchase Agreement. In addition, royalties due toAnaptysBio from GSK's global net sales of ZEJULA (niraparib) are excluded from the Royalty Purchase Agreement. The closing of the transaction is subject to the satisfaction of customary closing conditions. The aggregate JEMPERLI royalties and milestones to be received by Sagard under this Agreement is capped at certain fixed multiples of the upfront payment based upon time. Once Sagard receives an aggregate of either$312.5 million (125% of the upfront) by the end of 2026, or$337.5 million (135% of the upfront) during 2027 or$412.5 million (165% of the upfront) at any time after 2027, the Royalty Purchase Agreement will expire resulting inAnaptysBio regaining all subsequent JEMPERLI royalties and milestones. The foregoing summary of the Royalty Purchase Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Royalty Purchase Agreement and the Collaboration Agreement. A copy of the Collaboration Agreement is available as Exhibit 10.10 toAnaptysBio's Registration Statement on Form S-1, as amended, filed onMay 10, 2016 and as Exhibit 10.16 toAnaptysBio's Annual Report on Form 10-K for the year endedDecember 31, 2020 . A copy of the Royalty Purchase Agreement will be filed as an exhibit toAnaptysBio's Annual Report on Form 10-K for the year endedDecember 31, 2021 . Forward-Looking Statements This filing contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, the timing and potential amount of milestones and royalty payments to be received under the Collaboration Agreement and benefits expected from the Royalty Purchase Agreement. Statements including words such as "anticipate," "may," "will," "to be," or "expect" and statements in the future tense are forward-looking statements. These forward-looking statements involve risks and uncertainties, as well as assumptions, which, if they do not fully materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such forward-looking statements. Forward-looking statements are subject to risks and uncertainties that may cause the company's actual activities or results to differ significantly --------------------------------------------------------------------------------
from those expressed in any forward-looking statement, including the risk that
the transaction with Sagard may not close when expected, or at all, and risks
and uncertainties described under the heading "Risk Factors" in documents the
company files from time to time with the
--------------------------------------------------------------------------------
© Edgar Online, source